Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme -- Ignore unavailable to you. Want to Upgrade?

To: Auricman who wrote (8628)	12/18/1998 4:27:00 PM
From: TheWay	Read Replies (1) \| Respond to of 8798

CNSI surged in the last 20 minutes...could be interesting This News not on Major wires yet: DJ: Cambridge NeuroScience to Announce Major Scientific Collaboration in Media (PR Newswire 12/18 14:54:48) Teleconference WHAT: Cambridge NeuroScience (Nasdaq: CNSI), Cambridge, MA, will be announcing an important collaboration with a major pharmaceutical company to develop a potentially important new treatment for neurodegenerative diseases: The new collaboration will address an important growth factor that has been demonstrated to stimulate in laboratory studies the growth of the myelin sheath, a protective insulation that is damaged or lost in several prevalent CNS diseases, including Multiple Sclerosis. Credentialed members of the media are invited to participate in an interactive media call to discuss the scientific and commercial elements of this partnership. WHEN: The media teleconference will begin at 10 AM (Eastern), Monday, December 21. The conference will last approximately one hour. Brief presentations will be followed by a question and answer period. TELEPHONE INFORMATION: Inside the US -- 1-800-283-1693 International -- 050-089-2521 PANEL: The conference will be moderated by Harry Wilcox, President and Chief Executive Officer, Cambridge NeuroScience, Inc., Cambridge, MA. Representatives of CNSI's new major pharma partner, and a scientific investigator will also be participating. THIS CALL IS AVAILABLE ONLY TO MEMBERS OF THE MEDIA. CONTACT: Harry W. Wilcox, President and Chief Executive Officer of Cambridge NeuroScience, Inc., 617-225-0600/ 14:41 ES S.PR CNSI I/BTC I/MTC N/PR N/PREL M/TEC P/DPH R/MA R/NME R/US R/USE